NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/28/2024
Back to search
Official data from USPTO
LAVA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LAVA THERAPEUTICS
ST13
US500000079354142Class
1, 5, 42, 44
Filing
79354142
Registration
7238557
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
09/28/2024
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
09/24/2021
Registration date
12/12/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/12/2023
Last transaction
12/12/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
NL
Examiner
PATEL, SAMIR
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Lava Therapeutics N.V.
Representatives
Robert R. Baron, Jr. Ballard Spahr LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Antibodies for scientific and research use; libraries of antibodies and collections of antibodies for scientific and research use; proteinsenzymesdiagnostic reagents for scientific and research usechemical and biochemical preparations and substances for use in the manufacture of medicines
Class 5
Pharmaceutical preparations for T-Cell therapy; pharmaceutical products for the prevention and treatment of cancer; immunotherapy productspharmaceutical preparations for the treatment of cancerautoimmune diseasesimmunological disorders; biological preparations for the treatment of cancer autoimmune diseasesimmunological disorders; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of cancerautoimmune diseases and immunological disorders; antibodies and libraries of antibodies for medical purposesfor treatment and/or diagnosis of cancerautoimmune diseases and immunological disorders
Class 42
Bio-technology and scientific servicesresearch and development services relating to bio-technology and science in the field of antibodiesproteins and enzymes; pharmaceutical research and development; biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research servicesantibodies evolving servicesprotein evolving services and enzyme evolving services; biochemistry research servicesantibodiesprotein and enzyme cataloging and antibodiesprotein and enzyme library services; laboratory research and medical laboratory testing services relating to the production of antibodiesproteins and enzymes
Class 44
Providing medical information about the treatment and/or diagnosis of cancerautoimmune diseases and immunological disorders via a website
Publications
History of USPTO decisions and trademark events.
34 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/08/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/14/2024
FIMP
FINAL DISPOSITION PROCESSED
03/14/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/12/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/26/2023
PUBO
PUBLISHED FOR OPPOSITION
09/26/2023
GPNX
NOTIFICATION PROCESSED BY IB
09/25/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/06/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/06/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/06/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/03/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/03/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/17/2023
RFNT
REFUSAL PROCESSED BY IB
02/15/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/20/2023
RFRR
REFUSAL PROCESSED BY MPU
01/20/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/11/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/11/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/11/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/11/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/13/2022
CNRT
NON-FINAL ACTION WRITTEN
11/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/08/2022
DOCK
ASSIGNED TO EXAMINER
11/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/04/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/03/2022
Continuous trademark protection
Get notified about every new filing that threatens LAVA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.